Trial · NCT02008877
Results by group25
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 25
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Dose Limiting Toxicities of Ganetespib When Administered in Combination With Sirolimus. | Ganetespib / Sirolimus | Dose Level 1 | 0 | DLTs | |
| Number of Dose Limiting Toxicities of Ganetespib When Administered in Combination With Sirolimus. | Ganetespib / Sirolimus | Dose Level 2 | 1 | DLTs | |
| Clinical Benefit of Ganetespib in Combination With Sirolimus | Ganetespib / Sirolimus | Phase 1 | 1 | Participants | |
| Clinical Benefit of Ganetespib in Combination With Sirolimus | Ganetespib / Sirolimus | Phase 2 | 0 | Participants | |
| Change in Plasma Pharmacokinetic Profile of Ganetespib and Sirolimus When Administered in Combination-Observed Maximum Plasma Concentration (Cmax) | Ganetespib / Sirolimus | Dose Level 1- Sirolimus trough | 12.1 | Standard Deviation 3.6 | ng/mL |
| Change in Plasma Pharmacokinetic Profile of Ganetespib and Sirolimus When Administered in Combination-Observed Maximum Plasma Concentration (Cmax) | Ganetespib / Sirolimus | Dose Level 2- Sirolimus trough | 12.5 | Standard Deviation 8.9 | ng/mL |
| Changes in Pharmacodynamic Parameters in Peripheral Blood Mononuclear Cells | Ganetespib / Sirolimus | Hsp70 at Baseline | 0.81 | Standard Deviation 0.39 | ratio |
| Changes in Pharmacodynamic Parameters in Peripheral Blood Mononuclear Cells | Ganetespib / Sirolimus | Hsp70 at Cycle 1 Day 15 | 0.84 | Standard Deviation 0.56 | ratio |
| Changes in Pharmacodynamic Parameters in Peripheral Blood Mononuclear Cells | Ganetespib / Sirolimus | pAKT at Baseline | 1.20 | Standard Deviation 0.70 | ratio |
| Changes in Pharmacodynamic Parameters in Peripheral Blood Mononuclear Cells | Ganetespib / Sirolimus | pAKT at Cycle 1 Day 15 | 1.44 | Standard Deviation 1.00 | ratio |
| Changes in Pharmacodynamic Parameters in Peripheral Blood Mononuclear Cells | Ganetespib / Sirolimus | p-S6 at Baseline | 1.25 | Standard Deviation 0.40 | ratio |
| Changes in Pharmacodynamic Parameters in Peripheral Blood Mononuclear Cells | Ganetespib / Sirolimus | p-S6 at Cycle 1 Day 15 | 0.54 | Standard Deviation 0.24 | ratio |
| Changes in Pharmacodynamic Parameters in Peripheral Blood Mononuclear Cells | Ganetespib / Sirolimus | p-eiF2alpha at Baseline | 1.02 | Standard Deviation 0.26 | ratio |
| Changes in Pharmacodynamic Parameters in Peripheral Blood Mononuclear Cells | Ganetespib / Sirolimus | p-eiF2alpha at Cycle 1 Day 15 | 0.49 | Standard Deviation 0.22 | ratio |
| Patient-reported Pain Severity and the Impact of Pain on Daily Activities | Ganetespib / Sirolimus | Baseline- Overall pain intensity | 7.5 | Full Range 0 to 10 | units on a scale |
| Patient-reported Pain Severity and the Impact of Pain on Daily Activities | Ganetespib / Sirolimus | Baseline- Tumor pain intensity | 7.5 | Full Range 0 to 10 | units on a scale |
| Patient-reported Pain Severity and the Impact of Pain on Daily Activities | Ganetespib / Sirolimus | Baseline- Pain interference | 6.49 | Full Range 0 to 10 | units on a scale |
| Patient-reported Pain Severity and the Impact of Pain on Daily Activities | Ganetespib / Sirolimus | Prior to Cycle 3- Overall pain intensity | 5 | Full Range 0 to 10 | units on a scale |
| Patient-reported Pain Severity and the Impact of Pain on Daily Activities | Ganetespib / Sirolimus | Prior to Cycle 3- Tumor pain intensity | 4.75 | Full Range 0 to 10 | units on a scale |
| Patient-reported Pain Severity and the Impact of Pain on Daily Activities | Ganetespib / Sirolimus | Prior to Cycle 3- Pain interference | 3.14 | Full Range 0 to 10 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02008877/results